Accessibility Menu
 
X4 Pharmaceuticals logo

X4 Pharmaceuticals

(NASDAQ) XFOR

Current Price$3.77
Market Cap$343.32M
Since IPO (2019)-99%
5 Year-98%
1 Year+25%
1 Month-15%

X4 Pharmaceuticals Financials at a Glance

Market Cap

$343.32M

Revenue (TTM)

$9.01M

Net Income (TTM)

$99.72M

EPS (TTM)

$-4.54

P/E Ratio

-0.80

Dividend

$0.00

Beta (Volatility)

1.32 (Average)

Price

$3.77

Volume

1,975

Open

$3.67

Previous Close

$3.64

Daily Range

$3.65 - $3.77

52-Week Range

$1.35 - $4.83

XFOR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About X4 Pharmaceuticals

Industry

Biotechnology

Employees

45

CEO

Adam R. Craig, MD, PhD

Headquarters

Boston, MA 02134, US

XFOR Financials

Key Financial Metrics (TTM)

Gross Margin

79%

Operating Margin

-11%

Net Income Margin

-11%

Return on Equity

-104%

Return on Capital

-40%

Return on Assets

-37%

Earnings Yield

-1.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$343.32M

Shares Outstanding

94.32M

Volume

1.98K

Avg. Volume

454.89K

Financials (TTM)

Gross Profit

$28.86M

Operating Income

$86.88M

EBITDA

$85.61M

Operating Cash Flow

$85.62M

Capital Expenditure

$3.00M

Free Cash Flow

$88.62M

Cash & ST Invst.

$253.00M

Total Debt

$77.28M

X4 Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.71M

-90.6%

Gross Profit

$2.11M

-91.1%

Gross Margin

77.92%

N/A

Market Cap

$343.32M

N/A

Market Cap/Employee

$2.40M

N/A

Employees

143

N/A

Net Income

$20.24M

-7277.7%

EBITDA

$20.07M

-124.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$232.99M

+2514.9%

Accounts Receivable

$1.11M

-5.2%

Inventory

$4.64M

+50.1%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$733.00K

-43.7%

Return on Assets

-36.90%

N/A

Return on Invested Capital

-39.65%

N/A

Free Cash Flow

$0.00

+100.0%

Operating Cash Flow

$19.60M

-58.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRSNMersana Therapeutics, Inc.
$29.08+0.00%
KPTIKaryopharm Therapeutics Inc.
$7.87+5.35%
KZRKezar Life Sciences, Inc.
$7.29+0.00%
OKUROnKure Therapeutics, Inc.
$3.65+10.61%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$14.14+0.03%
TET1 Energy Inc.
$8.61+0.25%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.84-0.03%
MARAMara Holdings
$13.18+0.06%

Questions About XFOR

What is the current price of X4 Pharmaceuticals?

X4 Pharmaceuticals is trading at $3.77 per share.

What is the 52-week range for X4 Pharmaceuticals?

Over the past 52 weeks, X4 Pharmaceuticals has traded between $1.35 and $4.83.

How much debt does X4 Pharmaceuticals have?

As of the most recent reporting period, X4 Pharmaceuticals reported total debt of $77.25M.

How much cash does X4 Pharmaceuticals have on hand?

X4 Pharmaceuticals reported $216.91M in cash and cash equivalents in its most recent financial results.

What is X4 Pharmaceuticals’s dividend yield?

X4 Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.